A new dawn for tovorafenib
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.